414,959 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, Holdings Channel reports. The fund bought 414,959 shares of the company’s stock, valued at approximately $3,287,000.

Several other institutional investors also recently modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC raised its holdings in Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in shares of Xeris Biopharma during the first quarter worth $170,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on XERS shares. Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Barclays boosted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Xeris Biopharma Stock Down 0.1%

Xeris Biopharma stock opened at $8.43 on Wednesday. The company has a 50 day moving average of $8.34 and a 200-day moving average of $6.95. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08. The stock has a market capitalization of $1.54 billion, a PE ratio of -76.64 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Insider Activity

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00. Following the completion of the transaction, the insider directly owned 1,691,126 shares of the company’s stock, valued at approximately $13,579,741.78. This trade represents a 5.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 275,998 shares of company stock worth $2,157,809. 4.35% of the stock is currently owned by insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.